These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26156055)

  • 1. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
    Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
    Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
    Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
    Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
    Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
    He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
    Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
    Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
    Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
    Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
    Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
    Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
    Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
    Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 17. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
    Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
    Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
    Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
    Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.